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Abstract 
Different studies have suggested that the nucleotide cyclic adenosine 3’, 5’-
monophosphate (cAMP) can actively play an important role as neuroprotective and anti-
inflammatory agent after a brain injury.  The phosphodiesterase 7 (PDE7) enzyme is 
one of the enzymes responsible for controlling specifically the intracellular levels of 
cAMP in the immune and central nervous systems. Therefore this enzyme could play an 
important role in brain inflammation and neurodegeneration. In this regard, using 
different chemical inhibitors of PDE7 we have demonstrated their neuroprotective and 
anti-inflammatory activity in different models of neurodegenerative disorders, including 
Parkinson disease (PD). In the present study, we have used the toxin 6-
hydroxydopamine (6-OHDA) and lipopolysaccharide (LPS) to model PD and explore 
the protective effects of PDE7B deficiency in dopaminergic neurons cell death. 
Lentivirus-mediated PDE7B deprivation conferred marked in vitro and in vivo 
neuroprotection against 6-OHDA and LPS toxicity in dopaminergic neurons, and 
preserved motor function involving the dopamine system in mouse. Our results 
substantiate previous data and provide a validation of PDE7B enzyme as a valuable new 
target for therapeutic development in the treatment of PD. 
 
Keywords: Inflammation, new target, oxidative stress, Parkinson Disease, PDE7B, 
shRNA. 
 
 
 
 
 3 
 
1. Introduction 
The cellular levels of cAMP areregulated by its formation by adenylcyclases and its 
hydrolysis by cyclic nucleotide phosphodiesterases (PDEs). Eleven families of PDEs, 
comprising multiple isoforms, hydrolyze cAMP and cGMP and have unique regulatory 
characteristics, cellular distribution, and sensitivity to inhibitors (Bender and Beavo, 
2006). Specifically PDE7 hydrolyzes cAMP and is highly expressed in endothelial 
cells, immune system, and brain (Lee, et al., 2002,Miro, et al., 2000,Miro, et al., 
2001,Sasaki, et al., 2004,Wang, et al., 2000). PDE7 is encoded by two genes, PDE7A 
and PDE7B which generate, by alternative splicing, several isoforms.Within the brain, 
PDE7 mRNA has been found in the cerebellum, olfactory bulb, dentate gyrus of the 
hippocampus and striatum, being PDE7B much more abundant than PDE7A 
(Johansson, et al., 2012,Lakics, et al., 2010).Our group has been the first to show that 
PDE7B protein is markedly induced in the Substantia Nigra pars compacta (SNpc) of 
adult rodents after a brain insult(Morales-Garcia, et al., 2011). There is relatively little 
information regarding the physiological role of PDE7B. It has been shown that PDE7B 
is involved in pro-inflammatory processes, in this regard it has been demonstrated that 
this enzyme can be a target for the control of neuroinflammation (Giembycz and Smith, 
2006). Additionally PDE7B is necessary for the induction of T-cell proliferation 
(Nakata, et al., 2002).  
cAMP signaling pathway is involved in different functions in the central nervous 
system, such as cellular growth, neuronal proliferation,and long-term memory 
formation (Lonze and Ginty, 2002). This nucleotide has also been shown to be a 
neuroprotective agent in different brain disorders, including neurodegenerative diseases 
such as Huntington, Alzheimer, and Parkinson disease (PD) (Bollen and Prickaerts, 
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2012,Morales-Garcia, et al., 2011,Volakakis, et al., 2010). Given the important role of 
cAMP in the brain, specific inhibitors ofPDEs are being analyzed as possible 
therapeutic targets for the treatment of different brain diseases (Garcia-Osta, et al., 
2012,Menniti, et al., 2006,Sharma, et al., 2013). During the last years, we have shown 
that different inhibitors of PDE7 are potent neuroprotective and anti-inflammatory 
agents in several animal models of neurodegenerative disorders, including PD (Castano, 
et al., 2009,Morales-Garcia, et al., 2011,Redondo, et al., 2012,Susin, et al., 2012). 
Parkinson disease is a devastating neurodegenerative disorder and the second most 
common neurodegenerative disease after Alzheimer disease. PD is characterized by the 
loss of dopamine producing neurons (dopaminergic neurons) in a specific brain region, 
the ventral midbrain (Schapira, 2009). Although the selective loss of dopaminergic 
neuron within the SNpc is the pathological hallmark of this disease, cell loss also takes 
place in other brain areas such as the locus coeruleus, dorsal nuclei of the vagus, among 
others (Damier, et al., 1999). Besides these sites, the whole nervous system is affected 
by the neurodegenerative process, according to the model of Braak et al (Braak, et al., 
2003), in many cases in a slow, progressive, ascending way. The impact of the whole 
nervous system justifies the many non-motor symptoms that often affect the patients in 
a similar or even greater way than the motor symptoms (Chaudhuri, et al., 2006). 
Because of this slowly progressive neurodegenerative process, PD is usually diagnosed 
when about at least 50% of dopaminergic neurons of the SNpc have degenerated and 
the others are already affected by the disease. So far, we have no treatments that prevent 
the development of PD or modify the detrimental course of the disease (“disease-
modifying agents”). Therapeutic options for PD are based on dopamine replacement, 
which reduces motor symptoms and alleviates associated depression and pain(Obeso, et 
al., 2010). However this pharmacological approach only leads to temporary, limited 
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improvement of patient’s quality of life, because chronic treatment with L-DOPA has 
severe side effects. Therefore, the discovery of new and improved therapies, based in 
the identification of new targets and novel drugs, remains a challenging issue for both 
Parkinson research community and pharmaceutical industry.  
As commented above, our group has been the first to show a potent neuroprotective and 
anti-inflammatory effect of different PDE7 chemical inhibitors in different animal 
models of PD (Morales-Garcia, et al., 2011,Susin, et al., 2012) suggesting that this 
enzyme could be a promising new therapeutic target for the treatment of this devastating 
disorder. In this work, we show that lentiviral-mediated delivery of PDE7B shRNA into 
the SNpc of adult mice protected 80% of dopaminergic neurons and decreased glial 
activation after an intranigral injection of lipopolysaccharide (LPS) or 6- 
hydroxydopamine (6-OHDA). Moreover, specific PDE7Bdepletion provides substantial 
improvement of behavioral deficits. Our data reveal that targeting specifically PDE7B 
can efficiently rescue dopaminergic neurons damage and provide further validation of 
the role of PDE7B enzyme as a promising new therapeutic target in PD. 
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2. Materials and Methods 
2.1. Construction of shRNA and cloning into lentiviral vectors. 
To knockdown PDE7 expression, two shRNA target sequences against PDE7B were 
obtained from Ambion (Life Techonologies). The selected interfering sequences used 
were the following: 1) shPDE7-1: 5'-GGCACATGCTCTCCAAAGT-3' (from 468 to 
488) and 2) shPDE7-2:  5’-CTGGAAATCAGTCCTCTTT-3’ (from 1,220 to 1,240) 
(GeneBank: AF AF190639.1) Annealed oligonucleotides were cloned into 
pGreenPuroTMshRNA lentiviral vector (Cloning and Expression Lentivector; SBI, 
System Biosciences), according to the manufacturer’s protocol, in which shRNA was 
expressed under the control of the H1 promoter. The control pGreenPuro™ construct 
with the Luciferase shRNA Template provided by System Biosciences was used as 
control in all the experiments. To obtain lentiviral particles, HEK-293T cells were 
transiently transfected with the appropriate lentiviral expression vectors and the third 
generation packaging vectors pMD2-G, pMDLg/pRRE, and pRSV-Rev. The medium 
containing lentiviruses was recovered after 36 hours post transfection, filtered through a 
0.22-μm filter and concentrated by ultracentrifugation using a Beckman SW28 
ultracentrifuge rotor for 2 hours at 20,000 r.p.m at 4ºC. The concentrated virus stocks 
were titered by flow citometry (FACS) on HEK-293T cells.  
 
2.2. Viral infection of SH-SY5Y cells. 
SH-SY5Y human neuroblastoma cells were propagated and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma) supplemented with 10% (v/v) fetal bovine 
serum (FBS), 10 mM L-Glutamine, and 5 mg/ml penicillin/streptomycin (Invitrogen) at 
37°C and 5% CO2. One day before infection, SH-SY5Y cells were seeded in 10-cm 
diameter tissue culture plates and used at approximately 70-80% confluence. Cells were 
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infected with shPDE7-1 or SH-PDE7-2 lentiviral particles, cultured in normal media 
and subjected to puromycin selection using a concentration of 2 g/mL. Positively 
selected cells were grown in medium containing 2 g/mL puromycin. 
 
2.3. Immunoblot analysis.  
Proteins were isolated from puromycin selected SH-SY5Y cell cultures by standard 
methods. Total protein extraction and western blot analysis was performed as 
previously described (Morales-Garcia, et al., 2011). Membranes were incubated 
overnight with a rabbit polyclonal specific anti-PDE7B antibody (1:1000; ProteinTech) 
with gently shaking at 4°C. The proteins were detected with the chemiluminescence 
detection system according to the manufacturer’s instructions using a secondary 
peroxidase-conjugated donkey anti-rabbit antibody (Amersham Biosciences). α-tubulin 
was used as a loading control. The band intensity was quantified with a densitometric 
scanner and values expressed as the average of the quantification of at least five 
independent experiments. 
 
2.4. Cell viability assay and nitrite measurement.  
Transfected SH-SY5Y cultures, after puromycin selection, were seeded at a density of 
3x10
4
 in 96-well plates and maintained on standard conditions. On attaining 
semiconfluence, cells were treated or not with 6-OHDA (35 µM, Sigma) for 16 h. Cell 
viability was measured using the MTT assay (Roche Diagnostic, GmbH), based on the 
ability of viable cells to reduce yellow MTT to blue formazan. The extent of reduction 
of MTT was quantified by absorbance measurement at 595 nm according to the 
manufacturer's protocol. Nitrite production was measured by Griess reaction. Briefly, 
culture supernatant was mixed with an equal volume of Griess reagent (Sigma- 
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Aldrich). Samples were then incubated at room temperature for 15 minutes and 
absorbance read using a plate reader at 492/540 nm. Each data point represents the 
mean ± s.d. of six replications in three different experiments. 
 
2.5. Animals.  
In vivo experiments were carried out with adult (2 to 3 month old) male C57BL/6 mice 
obtained from our breeding facilities (normative ES280790000188).  The animal 
protocols used in this study, as well as the overall mouse husbandry practices, were 
approved by the respective institutional animal care and use committees at Consejo 
Superior de Investigaciones Cientificas, in accordance with national (normative 
1201/2005) and international recommendations (normative 86/609 from the European 
Communities Council). All efforts were made to minimize animal suffering and to 
reduce the number of animals used.  
 
2.6. Injection of lentiviral particles in vivo. 
The animals (at least 12 mice in each group) were anaesthetized and placed in a 
stereotaxic apparatus (Kopf Instruments, CA). LPS (10 g in 2.5 l PBS) or 6-OHDA 
(5g in 2.5 l PBS containing 0.02% ascorbic acid) in combination with shPDE7-2 or 
control non-targeting shRNA lentiviral particles (1 x 10
6
 IU/animal) were injected into 
the right side of the SNpc (coordinates from Bregma: posterior – 3.2 mm; lateral + 2.0 
mm; ventral: +4.7 mm), according to the atlas of Paxinos and Franklin (Paxinos and 
Franklin, 2001). Animals injected only with non-targeting shRNA were used as controls 
throughout all the in vivo experiments. Mice were then housed to recover and sacrificed 
at 3, 7 and 45 days after lesioning. 
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2.7. Histology and Immunohistochemistry.  
Brains were processed as previously described (Morales-Garcia, et al., 2011). Briefly, 
after perfusion of the animals with 4% paraformaldehyde, brains were removed, 
postfixed in the same solution at 4 °C overnight, cryoprotected in 30% sucrose, frozen, 
and finally 30 μm coronal sections were obtained using a cryostat. Brain sections were 
stained with cresyl violet (Nissl stain) or used for immunohistochemistry. 
Immunofluorescence analysis in brain sections were performed as previously described 
(Cortes-Canteli, et al., 2008) and the images were acquired using a Radiance 2100 
confocal microscope (Bio-Rad, Hercules, CA). To compare fluorescence signals from 
different preparations, confocal microscope settings were fixed for all samples within 
the same analysis and adjusted to produce the optimum signal-to-noise ratio. For single 
immunofluorescence analysis (Figures 2, 3, 5 and 6) the antibodies used were: rabbit 
polyclonal anti-tyrosine-hydroxylase (TH) (1/200; Chemicon/Millipore) followed by a 
secondary Alexa-Fluor546 goat anti-rabbit (Temecula, CA), goat polyclonal anti-
PDE7B (1/100; Santa Cruz Biotech, USA) followed by a secondary Alexa-Fluor546 
horse anti-goat and rabbit polyclonal anti-serine 133 P-CREB (1/200; Cell Signaling) 
followed by a secondary Alexa-Fluor488 goat anti-rabbit. Triple immunofluorescences 
(Figures 8 and 9) to detect astroglial and microglial cells (together with TH) were 
performed in the same sections and the antibodies used were: rabbit polyclonal anti-TH 
(1/200; Chemicon/Millipore) followed by a secondary Alexa-Fluor488 goat anti-rabbit, 
mouse anti-glial fibrillary acidic protein(GFAP) (1/300; Sigma, Germany) followed by 
a secondary Alexa-Fluor 647 goat anti mouse, and microglial cells were stained with 
Texas Red (emission at 546) Lycopersiconesculentum (tomato-lectin; 1/300; Vector 
Labs. USA). All secondary antibodies were used at 1/500. Neuronal integrity and 
specifically the extension of dopaminergic cell death was performed by counting Nissl-
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stained and TH-positive cells, respectively, in the SNpc in five well-defined high 
magnification (×400) fields per animal, using a computer-assisted image analysis 
software (Soft Imaging System Corp). The extent of gliosis was quantified as 
previously described (Morales-Garcia, et al., 2009). 
 
2.8. Stereological cell counting. 
In addition, dopaminergic neuronal loss was also estimated by using unbiased 
stereology according to the optical fractionator method (West, et al., 1991). This 
method of cell counting is not affected by either the volume of the reference (SNpc) or 
the size of the counted elements. The number of TH+ cells was counted in a 1:5 series 
of sections across the rostro-caudal extent of the SNpc after TH staining using the DAB 
method. The stereology system consists of an Olympus BX51 microscope fitted with a 
XZY motorized computer stage (Prior ProScan, Rockland, MA), a digital microcator 
(Heidenhain, Schaumburg, IL), and the CAST-2 Stereological software (Olympus, 
Tokyo). Neurons were counted twice with the observer blind to the experimental group. 
To avoid double counting of neurons, TH-stained cells were counted only when their 
nuclei were optimally visualized. The sampling was performed according to unbiased 
stereological principles using a 100x100 µm step length and a counting frame. The total 
positive cell number (N) will be estimated using the equation: N= sumQ- x 1/ssf x 1/asf 
x 1/tsf, where sumQ- is the total number of neurons counted with the fractionator, ssf is 
the section sampling fraction, asf is the sampling fraction area, and tsf is the sampling 
fraction thickness. The reliability of the sampling scheme will be calculated to confirm 
that the coefficient of error is <0.1 (Tapia-Gonzalez, et al., 2011,Tapia-Gonzalez, et al., 
2013). Results were expressed as the percentage of TH-immunoreactive cells relative to 
the uninjected side. 
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2.9. Behavioral testing.  
Apomorphine-induced rotational behavioral test was performed 4 weeks following LPS 
or 6-OHDA lesioning of the SNpc. Mice were given a subcutaneous injection of 
apomorphine at a dose of 0.5 mg/kg (Sigma), placed in individual glass bowls with a 
diameter of 20 cm and rotation was monitored for 40 min. Analysis of completed (360°) 
rotations was made offline and expressed as the number of contralateral net turns per 
minute. Mice showing more than six turns per minute were considered as severely 
lesioned (Grealish, et al., 2010).Three different experiments with at least 12 
animals/experimental group were performed. Results were expressed as the number of 
contralateral turns per minute. 
 
2.10. Statistics Analysis.  
The SPSS statistical software package (version 20.0) for Windows (Chicago, IL) was 
used for the ANOVA analyses. Statistical comparisons for significance among different 
groups of animals were performed by ANOVA followed by Newman−Keuls' test for 
multiple comparisons. Student’s t-test was used to analyze statistical differences 
between cells. Differences were considered statistically significant at p < 0.05. 
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3. Results 
3.1. Neuroprotective and anti-inflammatory effects of PDE7B gene silencing in 
SH-SY5Y cultures. 
The human dopaminergic neuronal cell line SH-SY5Y has been described as an ideal 
system for modeling in vitro the characteristics of dopaminergic neuron since they have 
many features of Substantia Nigra neurons (Takahashi, et al., 1994). To study the role 
of PDE7B gene silencing on dopaminergic neurons death and inflammation, we 
infected SH-SY5Y cultures with lentiviral particles containing two different sequences 
targeting PDE7B (shPDE7-1 and shPDE7-2), as described in Material and Methods. We 
first validated by Western blot the effectiveness of both sequences used. Figure 1A 
shows that infection of SH-SY5Y cells with shPDE7-2 led to a drastic reduction of the 
targeted enzyme (68% decrease in PDE7B protein levels). This reduction was much 
lower in those cultures infected with shPDE7-1 (24% decrease). We next evaluated the 
effect of the two lentiviral constructs, shPDE7-1 and shPDE7-2, on the cell death 
induced by 6-OHDA. The treatment with this toxin led to a 41% loss of cell viability, as 
measured by the MTT assay (Figure 1B). Cells infected with lentiviral particles 
containing a non-targeting shRNA were used as controls. As can be seen in Figure 1B, 
infection of SH-SY5Y cells with shPDE7-1 did not have any effect on the loss of cell 
viability after 6-OHDA treatment, which is in accordance with the low levels of 
interference obtained with this sequence. However, when cells were infected with 
shPDE7-2 lentiviral particles a significant neuroprotective effect was observed. These 
results suggest that PDE7B gene silencing protects the human dopaminergic neuronal 
cell line SH-SY5Y from 6-OHDA-induced cell death. Cytotoxicity induced by 6-
OHDA is frequently accompanied by a pronounced inflammatory activity. Then, we 
next evaluated the potential anti-inflammatory effect of silencing the PDE7B gene by 
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measuring the production of nitrites in 6-OHDA-treated SH-SY5Y cells. Again, as 
happened with cell viability, shPDE7-2 significantly reversed the increase in nitrite 
production elicited by 6-OHDA treatment, whereas infection with shPDE7-1 did not 
have any significant effect (Figure 1C). These results demonstrate that silencing PDE7B 
gen results in a blockade of the 6-OHDA-induced cell death and the subsequent 
inflammatory process. 
 
3.2. Injection of shPDE7B in the SNpc of adult mice significantly reduces PDE7B 
induction by LPS and 6-OHDA and increases CREB phosphorylation. 
In view of the results obtained in vitro suggesting a neuroprotective and anti-
inflammatory effect of shPDE7-2 on dopaminergic cells, we next examined the role of 
PDE7B gene silencingin two clinically relevant models of Parkinson disease (PD). 
First, we analyzed the efficacy of shPDE7-2, since this construct was the most efficient 
in the in vitro studies, on PDE7 protein levels in the SNpc. To this end, adult mice were 
injected into the SNpc with lentiviral particles containing a non-targeting shRNA 
(control) or shPDE7-2 in combination with LPS or 6-OHDA and the expression of 
PDE7B was evaluated at days 3, 7 and 45 after injury. We found low levels of PDE7B 
in SNpc in control mice (Figure 2). However, mice lesioned with LPS or 6-
OHDArevealed an increase in PDE7B protein levels, compared to the control group. 
This increase is clearly observed 3 days after injury and maintained at 7 and 45 days. 
These results are consistent with those previously described by our group in a similar 
model (Morales-Garcia, et al., 2011). When LPS (Figure 2A) or 6-OHDA (Figure 2B) 
were injected together with shPDE7-2, a dramatic decrease in PDE7B induction in the 
SNpc was observed. These results are in agreement with our previous observations 
showing that chemical inhibition of PDE7 by direct administration of the PDE7 
 14 
inhibitor S14significantly decreases the induction of PDE7 after LPS treatment 
(Morales-Garcia, et al., 2011). 
Since as expected, PDE7B interference will increase cAMP levels, we next analyzed the 
phosphorylation of the cAMP response element-binding protein (CREB), a well-known 
target of the cAMP signaling pathway. Our results clearly show (Figure 3) that 
intranigral infection with shPDE7-2lentivirus causes a major and sustained increase in 
the levels of phospho-CREB. This increase was observed at 3, 7 and 45 days after viral 
infection; no increase was observed in animals infected with the non-targeting control 
virus or animals lesioned with LPS or 6-OHDA (Figure 3). 
 
3.3. Intranigral delivery of shPDE7-2 lentivirus protects dopaminergic neurons 
from LPS- or 6-OHDA-induced neuronal death.  
To assess the potential neuroprotective role of PDE7B gene silencing in these animal 
models, we first carried out a histological analysis to evaluate the extent of neuronal cell 
loss in the SNpc of the different groups of animals (Figure 4). Quantification of the 
cresyl-violet stained cells showed that LPS (Figure 4A) and 6-OHDA (Figure 4B) 
injection resulted in a significant reduction in the number of neurons in the SNpc, in 
comparison with control animals. RNAi-mediated inhibition of PDE7B expression by 
shPDE7-2 led to substantial neuroprotection, and no significant differences were 
observed between control non-lesioned animals and LPS-lesioned animals infected with 
shPDE7-2 (Figure 4). To confirm that the neuronal death observed using Nissl staining 
corresponded to dopaminergic neurons, we performed immunohistochemistry analysis 
using an antibody against tyrosine hydroxylase (TH), to specifically stain dopaminergic 
neurons in the SNpc and dopaminergic fibers in the Striatum (Figure 5 and 6). As 
expected, after LPS or 6-OHDA injection, a substantial loss of dopaminergic cells in the 
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SNpc was observed, as compared with control animals at all times analyzed (3, 7 and 45 
days). In contrast, in animals injected with shPDE7-2 lentiviral particles together with 
LPS or 6-OHDA, no significant loss in dopaminergic cell number was observed. In 
accordance with these data, a parallel changes in TH staining were observed in the 
striatum (Figures 5, 6). Indeed, a marked reduction in the intensity of tyrosine 
hydroxylase innervation in the striatum was only observed in mice injected with LPS or 
6-OHDA and the control lentivirus. Additionally, we have performed unbiased 
stereological determination of the number of TH+ neurons in the SNpc. The results 
obtained are shown in Figure 7. As can be observed LPS- or 6-OHDA lesion reduced 
the number of dopaminergic neurons at all times analyzed and shPDE7-2 injection 
resulted in a remarkable neuronal protection.  Overall, these results indicate that PDE7B 
gene silencing has significant neuroprotective effects of dopaminergic cells in the SNpc 
and also in its dopaminergic fibers projecting to the striatum, and validate our previous 
results showing a strong prevention of dopaminergic injury by chemical PDE7 
inhibitors. 
 
3.4. Intranigral delivery of shPDE7-2 lentivirus significantly reduces LPS- and 6-
OHDA-induced glial activation. 
The loss of dopaminergic neurons in the SNpc as a consequence of hyperactivation of 
the surrounding glial cells has been widely described (Castano, et al., 1998,Herrera, et 
al., 2000,Iravani, et al., 2005,Qin, et al., 2007). Since one of the events that takes place 
in the SNpc after LPS and 6-OHDA injury is the activation of the glial cells and the 
subsequent release of pro-inflammatory factors in this area of the brain, which is in part 
responsible for the ongoing dopaminergic cell degeneration (Hunter, et al., 2009), we 
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next analyzed the expression of glial fibrillary acidic protein (GFAP), as a marker of 
astroglialcells (Figure 8), and tomato-lectin (Figure 9) to detect microglial activation. 
Concerning astrogliosis, resting astrocytes were detected around the SNpc of control 
animals. After LPS (Figure 8A) or 6-OHDA (Figure 8B) injury, a dramatic increase in 
GFAP immunoreactivity was detected in the same area. This increase in astrogliosis 
was absent after silencing of PDE7B, and the pattern of GFAP immunostaining in these 
animals was indistinguishable from that of control animals. Quantification of the data 
when LPS was used revealed a 54- and 63-fold decrease in both the number of strongly 
GFAP-positive astrocytes and staining intensity, respectively, in the shPDE7-2-injected 
mice, compared with the control group (Figure 8A). Similar results were obtained using 
the 6-OHDA animal model.6-OHDA-lesioned animals injected with shPDE7-2 
presented a number of GFAP
+
 cells and staining intensity quite similar to that observed 
in control mice (Figure 8B). 
Microglial cells (identified as tomato lectin-positive cells) (Figure 9) were almost 
undetectable in control non-targeting shRNA-injected animals. However, after LPS 
(Figure 9A) or 6-OHDA (Figure 9B) injection, a high tomato lectin signal was clearly 
detected in the SNpc. As observed with astroglial activation, this strong microgliosis 
was completely abrogated in those animals injected with shPDE7-2 lentiviral particles. 
Altogether, these data reinforce our hypothesis that targeting PDE7B can ameliorates 
PD progression, not only by directly preserving dopaminergic cells, but also 
diminishing the subsequent harmful inflammatory process. 
Finally, we studied the effect of PDE7 gene silencing on rotational behavior in mice, as 
a measurement of motor alterations induced by LPS- and 6-OHDA-injection (Figure 
10). To this end, 45 days after lesion mice were injected with apomorphine, which is 
known to induce contralateral rotational behavior in denervated animals. A significant 
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increase in the number of contralateral turns per minute following apomorphine 
administration was detected in those animals lesioned with LPS (Figure 10A) or 6-
OHDA (Figure 10B), compared with control mice. Remarkably, RNAi-mediated 
inhibition of PDE7B expression by shPDE7-2 led to substantial attenuation of the 
asymmetric motor behavior in both animal models of Parkinson´s disease. 
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4. Discussion 
PD is characterized by the progressive loss of dopaminergic neurons and currently there 
are not effective therapies to stop this process. Treating PD is still one of the main 
unmet medical needs and currently available therapies may stabilize the symptoms for 
some years but they are not able to significantly modify the course of the disease. 
Dopamine replacement with levodopa treatment helps to alleviate some of the motor 
problems but dopamine-producing neurons continue to die and the neurodegenerative 
disorder gets worse (Obeso, et al., 2010). Therefore identification of new therapeutic 
targets which can slow or halt the progression of the disease is of upmost importance. 
Chemical genetic screens allow for the discovery of small molecules that provide lead 
compounds for novel therapies; however identification of the mechanistically relevant 
targets and their validation remain a major experimental challenge. Accordingly with 
our previous results showing a neuroprotective effect of PDE7 inhibitors in PD 
(Morales-Garcia, et al., 2011) here we found that RNAi-mediated depletion of PDE7B 
results in a neuroprotection of dopaminergic cells and attenuates glial activation in two 
different models of PD. These results point to PDE7B as a new valuable target for novel 
treatments of this disease. 
The experimental system we have employed involves lentivirus-mediated gene transfer 
of a shRNA specific for PDE7Bin vitro and in two in vivo animal models of PD. We 
initially analyzed the potential neuroprotective and anti-inflammatory effects of PDE7B 
depletion in the human dopaminergic cell line SH-SY5Y. Human neuroblastoma SH-
SY5Y cells exposed to 6-OHDA are used as in vitro model for PD, due to the fact that 
similar cellular processes occur in the degenerating dopaminergic neurons (Ouyang and 
Shen, 2006). We show that infection with shRNA lentiviral particles resulted in a 
significant reduction in 6-OHDA-induced neuronal cell death and in a decrease in nitrite 
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liberation after LPS treatment. A clear difference was observed between shPDE7-1 and 
shPDE7-2 in PDE7B reduction and cell protection. The reason why Seq 1 was not very 
effective may relay in the fact that the structural character of siRNA molecules might be 
an important determinant of siRNA efficiency. For reasons that are unclear, some 
siRNAs work better tan others. This efficiency is largely determined by a number of 
factors. In particular it depends upon the siRNA nucleotide composition. Thus, 
whatever the reason, we continued our in vivo studies using shRNA-2 since it was the 
most efficient in the in vitro studies. These results are consistent with our previous 
study indicating that S14, an inhibitor of PDE7, eliminated 6-OHDA-induced cell death 
and nitrite production (Morales-Garcia, et al., 2011). 
To evaluate the in vivo relevance of the abovementioned cellular effects, the anti-
inflammatory and neuroprotective effects of direct administration of PDE7 shRNA 
lentiviral particles into the SNpc of adult mice were assayed in two classical rodent 
models of PD: unilateral stereotaxic injection of LPS (inflammatory model) or 6-OHDA 
(oxidative stress model) injection into the SNpc of adult mice. The treatment with LPS 
leads to a loss of dopaminergic cells and activation of astrocytes and microglial cells 
with the subsequent release of neurotoxic factors (Dutta, et al., 2008,Kim, et al., 
2000,McCoy, et al., 2006). 6-OHDA injection into the SNpc of rodents causes the 
destruction of the nigrostriatal pathway, mediated by an oxidative stress with a result of 
a loss of dopaminergic input to the striatum (Blandini, et al., 2008,Deumens, et al., 
2002,Kirik, et al., 1998). Here, we show that injection of lentivirus shRNA targeting 
PDE7B into the SNpc of adult rats lesioned with 6-OHDA or LPS rescued 
dopaminergic neurons from cell death and considerably reduces the associated 
neuroinflammation. Importantly, depletion of PDE7B levels by lentiviral delivery of 
PDE7 shRNA significantly ameliorates the motor impairment subsequent to 
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dopaminergic cell loss. Previous results from our group demonstrate that chemical 
inhibition of PDE7 trigger neuroprotection and diminish neuroinflammation in different 
models of brain diseases, including PD (Castano, et al., 2009,Morales-Garcia, et al., 
2011,Redondo, et al., 2012,Susin, et al., 2012). Other authors have shown a 
neuroprotective effect of PDE inhibitors in neurodegenerative disease causing motor 
disorders (Sharma, et al., 2013).The cAMP phosphodiesterase4 (PDE4) has been also a 
target of study for therapy of motor disorders. Specifically PDE4 inhibitors have been 
shown to be neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) murine model of PD (Yang, et al., 2008) and in 3-nitropropionic acid (3-NP) 
induced experimental Huntington's disease in rats (Thakur, et al., 2013). However, and 
in contrast with PDE7, targeting PDE4 has been unsuccessful in clinical trials due to 
their side effects such as nausea and emesis. 
The results presented here further demonstrate the feasibility of PDE7B as a potential 
therapeutic target to accomplish dopaminergic cell protection in PD, and represent a 
functional validation of this target. Importantly, our findings support the proposition 
that the PDE7 enzyme is important in dopaminergic cell death and identify this enzyme 
as a therapeutic target for amelioration of dopaminergic injury and motor deficits 
associated to PD. Since inflammation and oxidative stress play a central role in the 
pathogenesis of different brain disorders and neuronal injury (Barone and Feuerstein, 
1999,del Zoppo, et al., 2000,Dutta, et al., 2008,Hanrott, et al., 2006,Hunter, et al., 
2009,Kim, et al., 2000,Rodriguez-Pallares, et al., 2007) our results suggest that 
inhibition of PDE7B could be of therapeutic value not only in PD but also in those brain 
diseases where inflammation and oxidative processes are involved. In this regard, it is 
interesting to mention that human genetic studies have point to an important role of 
PDE7Bin schizophrenia (Torri, et al., 2010). 
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This neuroprotective effect of PDE7B silencing is also in accordance with previous 
finding showing that cAMP signaling pathway ameliorates cell death in several 
neurodegenerative disorders. There is evidence showing a clear involvement of protein 
kinase A in neuroprotection (Lee, et al., 2005,Stetler, et al.) and that activation of CREB 
by this kinase is necessary for neuronal survival and axonal growth in different neuronal 
populations (Lonze and Ginty, 2002). 
Collectively, our findings clearly support the proposition that the PDE7B enzyme is 
important in dopaminergic cell death and identify this enzyme as a therapeutic target for 
amelioration of dopaminergic injury and motor deficits associated to PD. Our data 
provide compelling reasons to accelerate chemical research approaches to identify new 
drugs which selectively target PDE7B and could prevent the PD progression, avoiding 
the side-effects of the conventional treatments and slow down the progression of the 
disease. 
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Figure legends 
Figure 1. Gene silencing of PDE7 has a neuroprotective and anti-inflammatory 
effect in SH-SY5Y cells. Cells were infected with lentiviral particles containing a non-
targeting shRNA (control) or with two shRNAs targeting PDE7B (shPDE7-1 and 
shPDE7-2). (A) PDE7Blevels were measured by Western blot 7 days after infection. 
Representative Western blot and quantification analysis are shown. Each data point 
represents the mean ±s.d. of five different experiments. 
***p≤0.001, versus control. (B) 
and (C) SH-SY5Y infected cultures were exposed to 6-hydroxydopamine (6-OHDA, 35 
μM) for 24h and cell viability and nitrite concentration determined, as indicated in 
Materials and Methods. Each data point represents the mean ± s.d. of six replications in 
three different experiments. 
*p≤0.05; ***p≤ 0.001, versus non-treated control cultures; 
###p≤ 0.001, versus 6-OHDA-treated control cultures. 
 
Figure 2. Injection of shPDE7-2 in the SNpc of adult mice significantly reduces 
PDE7B induction in in vivo models of Parkinson's disease. Mice were injected into 
the SNpc with lentiviral particles containing non-targeting shRNA (control) or shPDE7-
2 in combination with (A) LPS (10 μg) or (B) 6-OHDA (5μg). After 3, 7 and 45 days 
animals were sacrificed and the brains processed for immunohistochemistry, as 
indicated in Material and Methods. Representative images of both hemispheres (contra- 
and ipsilateral) showing PDE7B expression (red) is shown. Nuclei were stained with 
DAPI. Scale bar, 100 μm. 
 
Figure 3. Injection of shPDE7-2 lentiviral particles in the SNpc of adult mice 
induces the phosphorylation of CREB in in vivo models of Parkinson's disease. 
Mice were injected into the SNpc with lentiviral particles containing non-targeting 
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shRNA (control) or shPDE7-2 in combination with (A) LPS (10 μg) or (B) 6-OHDA (5 
μg). After 3, 7 and 45 days brains were isolated and p-CREB immunodetected as 
indicated in Material and Methods. Representative images of ipsilateral coronal sections 
showing p-CREB expression (green) are shown. Nuclei were stained with DAPI. Scale 
bar, 100 μm. 
 
Figure 4. Gene silencing of PDE7B preserves neuronal cell death after LPS- or 6-
OHDA-induced toxicity. Mice were injected into the SNpc with lentiviral particles 
containing non-targeting shRNA (control) or shPDE7-2 in combination with (A) 
LPS(10 μg) or (B) 6-OHDA (5μg). After 45 days brains were removed and coronal 
sections processed for Nissl staining to label neurons. Scale bars, 500 μm. 
Quantification of the numbers of Nissl-stained cells in the SNpc, as described in 
Materials and Methods, is shown. Values represent the mean ± s.d. from three different 
experiments and five animals/experiment/experimental groups. 
***p≤ 0.001, versus 
vehicle-injected control animals; 
###p≤ 0.001, versus LPS-, or 6-OHDA-injected 
animals.
 
 
Figure 5. Gene silencing of PDE7B protects dopaminergic neurons of the SNpc and 
its striatal terminals against LPS- induced toxicity. Mice were injected into the SNpc 
with lentiviral particles containing non-targeting shRNA (control) or shPDE7-2 in in 
combination with LPS(10 μg). After 3, 7 and 45 days brains were removed and coronal 
sections processed for tyrosine hydroxylase (TH) immunoreactivity to label 
dopaminergic neurons in the SNpc or dopaminergic striatal fibers density (red). Scale 
bar, 100 μm. Quantification of the numbers of TH-immunoreactive (THir) neurons in 
the SNpc, as described in Materials and Methods is shown. Values represent the mean ± 
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s.d. from three different experiments and five animals/experiment/experimental 
groups.
***p≤ 0.001, versus vehicle-injected control animals; ###p≤ 0.001, versus LPS-, 
or 6OHDA-injected animals. 
 
Figure 6. Gene silencing of PDE7B protects dopaminergic neurons of the SNpc and 
its striatal terminals against 6-OHDA- induced toxicity. Mice were injected into the 
SNpc with lentiviral particles containing non-targeting shRNA (control) or shPDE7-2 in 
combination with 6-OHDA (5μg). After 3, 7 and 45 days brains were removed and 
coronal sections processed for tyrosine hydroxylase (TH) immunoreactivity to label 
dopaminergic neurons in the SNpc or dopaminergic striatal fibers density (red). Scale 
bar, 100 μm. Quantification of the numbers of TH-immunoreactive (THir) neurons in 
the SNpc, as described in Materials and Methods, is shown. Values represent the mean 
± s.d. from three different experiments and five animals/experiment/experimental 
groups,
***p≤ 0.001, versus vehicle-injected control animals; ###p≤ 0.001, versus LPS-, 
or 6-OHDA-injected animals. 
 
Figure 7. Gene silencing of PDE7B protects dopaminergic neurons of the SNpc 
against LPS- or 6-OHDA-induced toxicity: stereological analysis. Mice were 
injected into the SNpc with lentiviral particles containing non-targeting shRNA 
(control) or shPDE7-2 in combination with (A) LPS (10 μg) or (B) 6-OHDA (5μg). 
After 3, 7 and 45 days brains were removed and coronal sections processed for tyrosine 
hydroxylase (TH) immunoreactivity to label dopaminergic neurons using DAB staining. 
A representative image at 7 days after injection is shown. Scale bar, 500 μm. 
Quantification of the numbers of TH-immunoreactive (THir) neurons in the SNpc was 
performed using stereological methods, as described in Materials and Methods. Values 
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represent the mean ± s.d. from three different experiments and five 
animals/experiment/experimental groups. 
***p≤ 0.001, versus vehicle-injected control 
animals; 
###p≤ 0.001, versus LPS-, or 6-OHDA-injected animals. 
 
Figure 8. Gene silencing of PDE7B significantly reduces astroglial activation in the 
SNpc after LPS or 6-OHDA injections. Immunostaining showing the expression of 
the astrogial marker GFAP (magenta) and tyrosine hydroxylase (TH, green) in the 
SNpc. Mice were injected with lentiviral particles containing non-targeting shRNA 
(control) or shPDE7-2 in combination with (A) LPS (10 μg) or (B) 6-OHDA (5μg). 
After 45 days animals were sacrificed and the brains processed as indicated in Materials 
and Methods. Representative images showing the expression of GFAP (magenta) and 
tyrosine hydroxylase (TH, green) are shown. Quantification of the numbers of GFAP
+
 
cells and their immunostaining intensity in the SNpc, as described in Materials and 
Methods, is shown. Values represent the mean ± s.d. from three different experiments 
and five animals/experiment/experimental group. 
***p≤ 0.001, versus vehicle-injected 
control animals; 
###p≤ 0.001, versus LPS-, 6-OHDA-injected animals. Nuclei were 
stained with DAPI. Scale bar, 200 μm. 
 
Figure 9. Gene silencing of PDE7B significantly reduces microglial activation in 
the SNpc after LPS or 6-OHDA injections. Immunostaining showing the expression 
of the microglial marker tomato lectin (red) and tyrosine hydroxylase (TH, green) in the 
SNpc. Mice were injected with lentiviral particles containing non-targeting shRNA 
(control) or shPDE7-2 in combination with (A) LPS (10 μg) or (B) 6-OHDA (5μg). 
After 45 days animals were sacrificed and the brains processed as indicated in Materials 
and Methods. Representative images showing the expression of tomato lectin (red) and 
 31 
tyrosine hydroxylase (TH, green) are shown. Quantification of the numbers of reactive 
microglial cells, as described in Materials and Methods, is shown. Values represent the 
mean ± s.d. from three different experiments and five animals/experiment/experimental 
group. 
***p≤ 0.001, versus vehicle-injected control animals; ###p≤ 0.001, versus LPS-, 6-
OHDA-injected animals. Nuclei were stained with DAPI. Scale bar, 200 μm. 
 
Figure 10. Effect of PDE7B silencing on rotational behavior in hemiparkinsonian 
mice. Mice were injected in the SNpc with lentiviral particles containing non-targeting 
shRNA (control) or shPDE7-2 in combination with vehicle, LPS (10μg) (A) or 6-
OHDA (5μg) (B). Three weeks after injection apomorphine-induced rotations were 
analyzed, as indicated in Materials and Methods. Values represent the mean ± s.d. from 
three different experiments. At least 12 animals/experimental group were 
evaluated.
***p≤ 0.001, versus vehicle-injected control animals; ###p≤ 0.001, versus LPS- 
or 6-OHDA-injected animals. 
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